Prostate cancer vaccines

Expert Review of Vaccines

Volumn 12, Issue 3, 2013, Pages 253-262

  Michael, Agnieszka ^a   Relph, Kate ^a   Annels, Nicola ^a   Pandha, Hardev ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

immune tolerance; immunotherapy; prostate cancer; tumor microenvironment; vaccines

Indexed keywords

ABIRATERONE; CABAZITAXEL; CANCER VACCINE; COMPLEMENTARY DNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; DOCETAXEL; ENZALUTAMIDE; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; INTERLEUKIN 10; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 7; IPILIMUMAB; PD 1; RILIMOGENE GALVACIREPVEC; RNA VACCINE; SIPULEUCEL T; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VIRUS VACCINE;

CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL INFILTRATION; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG DOSE ESCALATION; FOLLOW UP; HUMAN; HYPOXEMIA; IMMUNE DEFICIENCY; IN VITRO STUDY; LIFE EXPECTANCY; MELANOMA; METASTASIS; MOLECULAR LIBRARY; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; TUMOR MICROENVIRONMENT;

AGED; CANCER VACCINES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; PROSTATE; PROSTATIC NEOPLASMS; TISSUE EXTRACTS; TREATMENT OUTCOME;

EID: 84875172362     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.13.27     Document Type: Review

References (92)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61(4), 212-236 (2011).
2. Kaehler KC, Piel S, Livingstone E, Schilling B, Hauschild A, Schadendorf D. Update on immunologic therapy with anti- CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin. Oncol. 37(5), 485-498 (2010).
3. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
4. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 376(9747), 1147-1154 (2010).
5. Mukherji D, Pezaro CJ, De-Bono JS. MDV3100 for the treatment of prostate cancer. Exp. Opin. Investig. Drugs 21(2), 227-233 (2012).
6. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
7. Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N. Engl. J. Med. 364(21), 2055-2058 (2011).
8. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012).
9. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513-1520 (2004).
10. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004).
11. Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J. Clin. Oncol. 29(27), 3677-3685 (2011).
12. Mercader M, Bodner BK, Moser MT et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc. Natl Acad. Sci. USA 98(25), 14565-14570 (2001).
13. Lilja H, Ulmert D, Vickers AJ. Prostatespecific antigen and prostate cancer: prediction, detection and monitoring. Nat. Rev. Cancer 8(4), 268-278 (2008).
14. Rigamonti N, Bellone M. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy. Cancer Immunol. Immunother. 61(4), 453-468 (2012).
15. Fukumura D, Duda DG, Munn LL, Jain RK. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 17(3), 206-225 (2010).
16. Barach YS, Lee JS, Zang X. T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics. Trends Mol. Med. 17(1), 47-55 (2010).
17. Gajewski TF. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13(18 Pt 1), 5256-5261 (2007).
18. Wittke F, Hoffmann R, Buer J et al. Interleukin 10 (IL-10): an immunosuppressive factor and independent predictor in patients with metastatic renal cell carcinoma. Br. J. Cancer 79(7-8), 1182-1184 (1999).
19. MacNeil IA, Suda T, Moore KW, Mosmann TR, Zlotnik A. IL-10, a novel growth cofactor for mature and immature T cells. J. Immunol. 145(12), 4167-4173 (1990).
20. Mehrotra PT, Donnelly RP, Wong S et al. Production of IL-10 by human natural killer cells stimulated with IL-2 and/or IL-12. J. Immunol. 160(6), 2637-2644 (1998).
21. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J.Exper. Med. 174(5), 1209-1220 (1991).
22. D'Andrea A, Aste-Amezaga M, Valiante NM, Ma X, Kubin M, Trinchieri G. Interleukin 10 (IL-10) inhibits human lymphocyte interferon gamma-production by suppressing natural killer cell stimulatory factor/IL-12 synthesis in accessory cells. J. Exper. Med. 178(3), 1041-1048 (1993).
23. Macatonia SE, Doherty TM, Knight SC, O'Garra A. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J. Immunol. 150(9), 3755-3765 (1993).
24. Itoh K, Hirohata S. The role of IL-10 in human B cell activation, proliferation, and differentiation. J. Immunol. 154(9), 4341-4350 (1995).
25. Cai G, Kastelein RA, Hunter CA. IL-10 enhances NK cell proliferation, cytotoxicity and production of IFN-gamma when combined with IL-18. Euro. J. Immunol. 29(9), 2658-2665 (1999).
26. Flores-Villanueva PO, Zheng XX, Strom TB, Stadecker MJ. Recombinant IL-10 and IL-10/Fc treatment down-regulate egg antigen-specific delayed hypersensitivity reactions and egg granuloma formation in schistosomiasis. J. Immunol. 156(9), 3315-3320 (1996).
27. Conrad CT, Ernst NR, Dummer W, Brocker EB, Becker JC. Differential expression of transforming growth factor beta 1 and interleukin 10 in progressing and regressing areas of primary melanoma. J. Exp. Clin. Cancer Res. 18(2), 225-232 (1999).
28. Moses HL, Yang EY, Pietenpol JA. TGFbeta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63(2), 245-247 (1990).
29. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Ann. Rev. Immunol. 16, 137-161 (1998).
30. Munn DH. Blocking IDO activity to enhance anti-tumor immunity. Front Biosci. Elite Ed. 4, 734-745 (2012).
31. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J. Immunother. 24(5), 392-407 (2001).
32. Saito H, Tsujitani S, Oka S et al. The expression of transforming growth factor-beta1 is significantly correlated with the expression of vascular endothelial growth factor and poor prognosis of patients with advanced gastric carcinoma. Cancer 86(8), 1455-1462 (1999).
33. Johnson B, Osada T, Clay T, Lyerly H, Morse M. Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. Curr. Mol. Med. 9(6), 702-707 (2009).
34. Gulley JL, Madan RA, Schlom J. Impact of tumor volume on the potential efficacy of therapeutic vaccines. Curr. Oncol. 18(3), e150-157 (2011).
35. Padhani AR, Ollivier L. The RECIST (Response Evaluation Criteria in Solid Tumors) criteria: implications for diagnostic radiologists. Brit. J. Radiol. 74(887), 983-986 (2001).
36. Hale DF, Clifton GT, Sears AK et al. Cancer vaccines: should we be targeting patients with less aggressive disease? Expert Rev. Vaccines 11(6), 721-731 (2012).
37. Knutson KL, Disis ML. Tumor antigenspecific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54(8), 721-728 (2005).
38. Hoos A, Eggermont AM, Janetzki S et al. Improved endpoints for cancer immunotherapy trials. J. Natl Cancer Inst. 102(18), 1388-1397 (2010).
39. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immunerelated response criteria. Clin. Cancer Res. 15(23), 7412-7420 (2009).
40. Michael A, Ball G, Quatan N et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin. Cancer Res. 11(12), 4469-4478 (2005).
41. Small E, Demkow T, Gerritsen WR et al. UCSF Comprehensive Cancer Center; Centrum Onkologii; VU Medisch Centrum; Centre Rene; Mount Vernon Hospital; University of Michigan Comprehensive Cancer Center; The Institute of Cancer Research; Cell Genesys, Inc. A Phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). ASCO Genitourinary Cancer Symposium, Orlando, FL, USA, 26-28 February 2009 (Abstract 7).
42. Higano CF, Saad B, Somer B; Seattle Cancer Care Alliance; Centre Hospitalier De L'Universite de Montreal; The West Clinic; The Oregon Clinic; Presbyterian Hospital; Johns Hopkins Sidney Kimmel; Central Georgia Cancer Care; Oncology Association of San Diego; ZNAMiddelhein; Cell Genesys. A Phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). ASCO Annual Meeting Proceedings, Orlando, FL, USA, 26-28 February 2009 (Abstract LBA150).
43. No authors listed. Cell Genesys reports long-term survival data in Phase II trial of GVAX. Expert Rev. Anticancer Ther. 2(3), 245-246 (2002).
44. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J. Biomed. Biotechnol. 2010(pii), 596432 (2010).
45. Weber JS, Vogelzang NJ, Ernstoff MS et al. A Phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J. Immunother. 34(7), 556-567 (2011).
46. Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J. Immunother. 33(6), 639-647 (2010).
47. Li L, Saade F, Petrovsky N. The future of human DNA vaccines. J. Biotechnol. 162(2-3), 171-182 (2012).
48. McNeel DG, Dunphy EJ, Davies JG et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 27(25), 4047-4054 (2009).
49. Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Rev. Vaccines 11(2), 189-209 (2012).
50. Hirschhorn-Cymerman D, Perales MA. Cytokine-FC fusion genes as molecular adjuvants for DNA vaccines. Methods Mol. Biol. 651, 131-155 (2010).
51. Best SR, Peng S, Juang CM et al. Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared with intramuscular injection and intradermal gene gun delivery. Vaccine 27(40), 5450-5459 (2009).
52. Chudley L, McCann K, Mander A et al. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time. Cancer Immunol. Immunother. 61(11), 2161-2170 (2012).
53. Pascolo S. Vaccination with messenger RNA. Methods Mol. Med. 127, 23-40 (2006).
54. Fotin-Mleczek M, Duchardt KM, Lorenz C et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34(1), 1-15 (2011).
55. Fotin-Mleczek M, Zanzinger K, Heidenreich R et al. Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. The J. Gene Med. 14(6), 428-439 (2012).
56. Mu LJ, Kyte JA, Kvalheim G et al. Immunotherapy with allo tumor mRNAtransfected dendritic cells in androgenresistant prostate cancer patients. Br. J. Cancer 93(7), 749-756 (2005).
57. Kübler H, Maurer T, Stenzl A. Final analysis of a Phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA. J. Clin. Oncol. 29(Suppl.), Abstract 4535 (2011).
58. Arlen PM, Gulley JL, Parker C et al. A randomized Phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin. Cancer Res. 12(4), 1260-1269 (2006).
59. Harrington LE, Most Rv R, Whitton JL, Ahmed R. Recombinant vaccinia virusinduced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76(7), 3329-3337 (2002).
60. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin. Invest. Drugs 18(7), 1001-1011 (2009).
61. Amato RJ. 5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy. Expert Opin. Biol. Ther. 10(2), 281-287 (2010).
62. Kottke T, Errington F, Pulido J et al. Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat. Med. 17(7), 854-859 (2011).
63. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012).
64. Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 antibodies in clinical trials. Expert Opin. Biol. Ther. 7(8), 1245-1256 (2007).
65. Persson J, Beyer I, Yumul R et al. Immunotherapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models. PloS ONE 6(7), e22303 (2011).
66. Lens M, Ferrucci PF, Testori A. Anti- CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Pat. Anticancer Drug Discov. 3(2), 105-113 (2008).
67. Ribas A. Anti-CTLA4 antibody clinical trials in melanoma. Update Cancer Ther. 2(3), 133-139 (2007).
68. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
69. Iwai Y, Terawaki S, Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Internat. Immunol. 17(2), 133-144 (2005).
70. van den Eertwegh AJ, Versluis J, van den Berg HP et al. Combined immunotherapy with granulocyte-macrophage colonystimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a Phase 1 dose-escalation trial. Lancet Oncol. 13(5), 509-517 (2012).
71. Thompson RH, Gillett MD, Cheville JC et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc. Natl Acad. Sci. USA 101(49), 17174-17179 (2004).
72. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
73. Yu P, Steel JC, Zhang M et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced interleukin-15 efficacy in a prostate tumor model. Proc. Natl Acad. Sci. USA 109(16), 6187-6192 (2012).
74. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61(11), 4497-4505 (2001).
75. Dranoff G, Mulligan RC. Activities of granulocyte-macrophage colonystimulating factor revealed by gene transfer and gene knockout studies. Stem Cells 12(Suppl. 1), 173-182 (disc.) 182-174 (1994).
76. Greiner JW, Guadagni F, Noguchi P et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science 235(4791), 895-898 (1987).
77. Burchill MA, Yang J, Vang KB, Farrar MA. Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol. letters 114(1), 1-8 (2007).
78. Oh S, Berzofsky JA, Burke DS, Waldmann TA, Perera LP. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces longlasting cellular immunity. Proc. Natl Acad. Sci. USA 100(6), 3392-3397 (2003).
79. Fry TJ, Mackall CL. Interleukin-7: master regulator of peripheral T-cell homeostasis? Trends Immunol. 22(10), 564-571 (2001).
80. Esche C, Subbotin VM, Maliszewski C, Lotze MT, Shurin MR. FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res. 58(3), 380-383 (1998).
81. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831), 1628-1632 (2007).
82. Gupta K, Cooper C. A review of the role of CpG oligodeoxynucleotides as Toll-like receptor 9 agonists in prophylactic and therapeutic vaccine development in infectious diseases. Drugs in R&D 9(3), 137-145 (2008).
83. Kmieciak M, Worschech A, Nikizad H et al. CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res. Treatment 126(2), 385-394 (2011).
84. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin. Biol. Ther. 12(10), 1383-1397 (2012).
85. Walter S, Weinschenk T, Stenzl A et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat. Med. (2012).
86. Litzinger MT, Fernando R, Curiel TJ, Grosenbach DW, Schlom J, Palena C. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccinemediated T-cell immunity. Blood 110(9), 3192-3201 (2007).
87. Bueno L, de Alwis DP, Pitou C et al. Semimechanistic modelling of the tumor growth inhibitory effects of LY2157299, a new Type I receptor TGF-beta kinase antagonist, in mice. Eur. J. Cancer 44(1), 142-150 (2008).
88. Kepp O, Galluzzi L, Martins I et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev. 30(1), 61-69 (2011).
89. Chakraborty M, Gelbard A, Carrasquillo JA et al. Use of radiolabeled monoclonal antibody to enhance vaccine-mediated antitumor effects. Cancer Immunol. Immunother. 57(8), 1173-1183 (2008).
90. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16(18), 4583-4594 (2010).
91. John J, Ismail M, Riley C et al. Differential effects of paclitaxel on dendritic cell function. BMC Immunol. 11, 14 (2010).
92. Huber ML, Haynes L, Parker C, Iversen P. Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl Cancer Inst. 104(4), 273-279 (2012).